Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against agilon health, inc. due to alleged violations of federal securities laws, encouraging affected investors to contact them for legal options [2][5]. Group 1: Legal Investigation - The law firm is looking into claims against agilon health, reminding investors of a deadline on March 2, 2026, to seek the role of lead plaintiff in a federal securities class action [2]. - The complaint alleges that agilon health and its executives made false or misleading statements regarding the company's financial guidance for 2025, which they knew was unattainable due to industry challenges [5]. Group 2: Financial Impact - On August 4, 2025, agilon health announced the suspension of its full-year 2025 financial guidance, leading to a significant stock price drop of 51.5% on August 5, 2025 [6]. - The company’s Executive Chair acknowledged that industry headwinds were more severe than previously anticipated, impacting the company's financial outlook [6]. Group 3: Investor Communication - Faruqi & Faruqi encourages anyone with information regarding agilon health's conduct, including whistleblowers and former employees, to reach out to the firm [8].

Philadelphia, Pennsylvania--(Newsfile Corp. - January 9, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) ("Integer" or the "Company") on behalf of investors who purchased or otherwise acquired Integer securities during the period of July 25, 2024 through October 22, 2025 (the "Class Period"), inclusive.Investor Deadline: Investors who purchased Integer securities during the Class Period may, no l ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Alexandria To Contact Him Directly To Discuss Their Options Alexandria issued a press release on October 27, 2025, reporting its financial results for the third quarter of 2025. Among other items, Alexandria reported third quarter earnings that fell short of analyst expectations, a 5% decline in revenue, and a 7% decline in adjusted funds from operation. Alexandria also reported a decline in it ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Blue Owl To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Blue Owl between February 6, 2025 and November 16, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Jan. 6, 2026 /PRNewswire/ -- Faruqi & F ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Sprouts Farmers Market, Inc. due to allegations of misleading statements regarding the company's growth potential and sales performance [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Sprouts between June 4, 2025, and October 29, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Sprouts, with a deadline of January 26, 2026, for investors to seek the role of lead plaintiff [2][6]. - The complaint alleges that Sprouts and its executives violated federal securities laws by making false statements and failing to disclose material adverse facts about the company's growth potential [4]. Group 2: Financial Performance - On October 29, 2025, Sprouts reported a 4.3% decrease in comparable store growth compared to the previous quarter, which was below the company's prior projections [5]. - The company projected a continued reduction in comparable sales growth for the fourth quarter, estimating only 0%-2% growth, and reduced its full-year expectations from 7.5%-9% to 7% [5]. - Following the disappointing financial results, Sprouts' stock price fell by $22.64 per share, opening at $81.91 [5].

Core Viewpoint - Trex Company, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and a significant drop in stock price [1][3]. Financial Performance - On November 4, 2025, Trex reported Q3 2025 net sales of $285 million, which was 5% below the mid-point of its guidance and a sequential decline of approximately 26% [3]. - The company experienced a 12% decline in net income per share for the nine months ending September 30, 2025, compared to the same period in the previous year [3]. - Trex revised its FY 2025 sales growth guidance down to roughly 0% compared to 2024, indicating a muted outlook for the fourth quarter [3]. Stock Market Reaction - Following the disappointing results, Trex's share price fell by $14.61, or about 31.07%, from $47.04 on November 4, 2025, to close at $32.43 on November 5, 2025 [3]. Company Strategy - Trex had previously assured investors that its revised inventory strategy would reduce volatility associated with channel stocking and de-stocking, and aimed for FY 2025 sales growth of 5% to 7% [2].

Core Insights - Rezolute, Inc. experienced a significant decline in its stock price following disappointing results from its Phase 3 sunRIZE clinical trial for its lead drug candidate, ersodetug, which failed to meet primary and key secondary endpoints [4][5] Group 1: Company Overview - Rezolute, Inc. is publicly traded on NASDAQ under the ticker RZLT [2] - The company is focused on developing treatments for congenital hyperinsulinism [4] Group 2: Clinical Trial Results - The Phase 3 sunRIZE clinical trial for ersodetug did not achieve statistically significant reductions in hypoglycemia events compared to placebo [4] - The highest dose in the trial showed reductions that were not statistically significant [4] Group 3: Stock Performance - On December 11, 2025, Rezolute's stock price plummeted from approximately $10.94 to an intraday low of around $0.90, marking an approximate 85-90% drop [5] - Trading was halted under Nasdaq's volatility controls due to the drastic decline [5]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Blue Owl Capital Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and undisclosed liquidity issues [2][4]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses in Blue Owl between February 6, 2025, and November 16, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Blue Owl, with a deadline of February 2, 2026, for investors to seek the role of lead plaintiff [2]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [7]. Group 2: Allegations Against Blue Owl - The complaint alleges that Blue Owl and its executives made false or misleading statements and failed to disclose significant issues, including pressure on its asset base from BDC redemptions and undisclosed liquidity problems [4]. - The company is reportedly facing the likelihood of limiting or halting redemptions of certain BDCs due to these issues [4]. Group 3: Market Impact and Investor Concerns - An article published by the Financial Times indicated that Blue Owl has blocked redemptions in one of its private credit funds, which could lead to significant losses for investors [5]. - Following the news of the merger and redemption restrictions, Blue Owl's stock price fell by $0.85, or 5.8%, closing at $13.77 per share on November 17, 2025 [6]. - Investors in Blue Owl Capital Corporation II will lose the ability to redeem cash at the fund's Net Asset Value (NAV) after the merger, as they will exchange shares for publicly traded Blue Owl shares, which are trading approximately 20% below NAV [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Primo Brands Corporation due to allegations of violations of federal securities laws related to misleading statements about the merger with BlueTriton Brands, which led to significant financial losses for investors [2][4]. Group 1: Allegations and Financial Impact - The complaint alleges that Primo Brands and its executives made false and misleading statements regarding the merger, claiming it would enhance growth and operational efficiencies, while failing to disclose integration issues [4]. - Problems began to surface on August 7, 2025, when Primo Brands reported Q2 2025 earnings, revealing disruptions in product supply and service due to the merger, resulting in a stock price drop of $2.41, or approximately 9%, from $26.41 to $24.00 [4][6]. - On November 6, 2025, the company significantly reduced its full-year 2025 net sales and adjusted EBITDA guidance, leading to a further stock decline of $8.20, or 36%, from $22.66 to $14.46 over two trading sessions [5][6]. Group 2: Legal Proceedings and Investor Actions - Investors who purchased securities during the specified class periods are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options for participating in the class action [1][2]. - The deadline for investors to seek the role of lead plaintiff in the federal securities class action against Primo Brands is January 12, 2026 [2]. - The lead plaintiff is defined as the investor with the largest financial interest who directs the litigation on behalf of the class, with the option for any class member to move the court to serve as lead plaintiff [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Bitdeer Technologies Group due to alleged violations of federal securities laws, particularly concerning misleading statements about the company's SEALMINER A4 project and its delayed chip development [4][6]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the February 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against Bitdeer [4]. - Investors who suffered losses in Bitdeer between June 6, 2024, and November 10, 2025, are encouraged to discuss their legal rights with the firm [4][10]. Group 2: Financial Performance and Stock Impact - Bitdeer reported a third-quarter earnings per share of -$1.28, missing the consensus estimate of -$0.22, which led to a stock price drop of $2.63 per share, or 14.9%, closing at $15.02 on November 11, 2025 [7]. - Following a fire incident at its construction facility, Bitdeer's stock fell another $2.83 per share, or 20.3%, closing at $11.11 on November 13, 2025 [8]. Group 3: Allegations of Misleading Information - The complaint alleges that Bitdeer and its executives failed to disclose critical information regarding the SEAL04 chip's energy efficiency and its expected mass production timeline [6].